Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,133Revenue $M20.9Net Margin (%)-270.6Z-Score25.6
Enterprise Value $M1,966EPS $-0.3Operating Margin %-273.0F-Score3
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-270.6Higher ROA y-yY
Price/Book9.410-y EBITDA Growth Rate %-0.6Quick Ratio5.5Cash flow > EarningsY
Price/Sales63.75-y EBITDA Growth Rate %-3.8Current Ratio5.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-31.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)7ROE % (ttm)-35.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M238ROI % (ttm)-57.0Gross Margin Increase y-yN

Gurus Latest Trades with NVAX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVAXJean-Marie Eveillard 2014-12-31 Sold Out -0.01%$4.05 - $5.98
($5.23)
$ 8.8369%Sold Out0
NVAXJean-Marie Eveillard 2014-06-30 Add$3.69 - $5.13
($4.39)
$ 8.83101%Add 150%500,000
NVAXDavid Swensen 2014-03-31 Sold Out -0.23%$4.13 - $6.65
($5.59)
$ 8.8358%Sold Out0
NVAXJean-Marie Eveillard 2014-03-31 Reduce-0.01%$4.13 - $6.65
($5.59)
$ 8.8358%Reduce -75%200,000
NVAXDavid Swensen 2013-12-31 Buy 0.23%$2.76 - $5.16
($3.51)
$ 8.83152%New holding, 25398 sh.25,398
NVAXGeorge Soros 2013-12-31 Sold Out -0.02%$2.76 - $5.16
($3.51)
$ 8.83152%Sold Out0
NVAXGeorge Soros 2013-09-30 Buy 0.02%$2.25 - $3.39
($2.82)
$ 8.83213%New holding, 573000 sh.573,000
NVAXJean-Marie Eveillard 2013-09-30 Buy 0.01%$2.25 - $3.39
($2.82)
$ 8.83213%New holding, 800000 sh.800,000
NVAXJean-Marie Eveillard 2011-03-31 Sold Out $2.15 - $2.96
($2.44)
$ 8.83262%Sold Out0
NVAXJean-Marie Eveillard 2010-09-30 Add$2.01 - $2.34
($2.2)
$ 8.83301%Add 25%125,000
NVAXJean-Marie Eveillard 2010-06-30 Reduce$2.18 - $2.97
($2.46)
$ 8.83259%Reduce -52.65%100,000
NVAXJean-Marie Eveillard 2009-12-31 Buy 0.01%$2.53 - $4.41
($3.46)
$ 8.83155%New holding, 250000 sh.250,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVAX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVAX Jean-Marie Eveillard 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


NVAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herrmann John A IIISVP, General Counsel 2015-01-31Buy9,869$2.28291.23view
Trizzino JohnSVP, Commercial Operations 2015-01-31Buy6,611$3.63145.73view
Hahn Timothy JonSVP, Manufacturing 2015-01-31Buy9,329$2.28291.23view
Wilson Russell PSVP, Business Development 2015-01-31Buy5,050$2.28291.23view
Glenn Gregory MSVP, Research and Development 2015-01-31Buy866$2.28291.23view
PHILLIPS BARCLAY ASVP, CFO 2015-01-31Buy8,388$2.28291.23view
Erck Stanley CCEO and President 2015-01-31Buy6,122$2.28291.23view
EVANS GARY CDirector 2014-12-16Sell46,701$5.7255.94view
EVANS GARY CDirector 2014-12-12Sell30,000$5.7754.59view
Modi Rajiv I.Director 2014-11-20Sell518,889$5.0277.69view

Press Releases about NVAX :

    Quarterly/Annual Reports about NVAX:

    News about NVAX:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 08 2015 
    comment on NVAX Mar 16 2013 
    comment on NVAX Mar 16 2013 
    Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
    Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
    Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
    creiter note on NVAX Jan 03 2010 
    Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
    Novavax Reports Second Quarter 2009 Financial Results Aug 07 2009 

    More From Other Websites
    NOVAVAX INC Files SEC form 10-K, Annual Report Feb 27 2015
    Novavax reports 4Q loss Feb 27 2015
    Novavax reports 4Q loss Feb 27 2015
    Novavax Reports Fourth Quarter and Year-End 2014 Financial Results Feb 26 2015
    Q4 2014 Novavax Inc Earnings Release - After Market Close Feb 26 2015
    4 Big Stocks on Traders' Radars: Hewlett-Packard and More Feb 26 2015
    Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on... Feb 19 2015
    Novavax Boosted by Ebola Vaccine Data Feb 17 2015
    [video]Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan Feb 13 2015
    Companies pushing Ebola vaccines through trials won't let up, says Novavax CEO Feb 13 2015
    Gaithersburg's Novavax begins Phase 1 Ebola vaccine trials Feb 12 2015
    Novavax starts Ebola vaccine trials on humans Feb 12 2015
    Novavax Announces Initiation of Ebola Vaccine Phase 1 Clinical Trial Supported by Non-Human Primate... Feb 12 2015
    Novavax (NVAX) Jumps: Stock Adds 6.4% in Session - Tale of the Tape Jan 16 2015
    Novavax Announces Management Promotion Jan 08 2015
    Novavax Announces Management Promotion Jan 08 2015
    Novavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
    Novavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
    Stock Market Video Analysis for Week Ending 12/12/14 Dec 12 2014
    Stock Market Video Analysis for Week Ending 12/5/14 Dec 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK